总肿瘤大小对表现为部分实性结节的临床IA期肺腺癌患者预后的影响:仅有实性部分大小重要吗?
该回顾性单中心研究纳入506例临床IA期表现为部分实性结节、行标准肺叶切除术的肺腺癌患者,分析总肿瘤大小、实性部分大小及临床T分期的预后价值。多因素Cox回归显示总肿瘤大小与cT1b的交互项及cT1c是复发的独立危险因素;cT1b中总肿瘤大小>3.0 cm者复发风险显著更差(HR=3.796),与cT1c无显著差异(p=0.915)。结论认为cT1b中总肿瘤大小>3.0 cm者应考虑升级分期。
要点
- cT1b中总肿瘤大小>3.0 cm者复发风险显著高于≤3.0 cm者(HR=3.796),与cT1c无显著差异(p=0.915)。
- 总肿瘤大小与cT1b的交互项(HR=1.091,p=0.019)及cT1c(HR=68.436,p=0.010)为复发独立危险因素。
- 当前T描述符在表现为部分实性结节的IA期腺癌中是强有力的预后因素。
核心结论
- 总肿瘤大小是cT1b无淋巴结或远处转移腺癌患者的显著预后因素,cT1b中总肿瘤大小>3.0 cm者的肺癌复发风险与cT1c相当。
研究设计与样本
- 回顾性研究,经机构审查委员会批准,纳入506例(男:女=200:306;中位年龄62岁)临床IA期腺癌谱部分实性结节患者,均在单一三级医疗中心接受标准肺叶切除术。
诊断标准与关键数值
- 多因素Cox回归显示总肿瘤大小与cT1b的交互项为复发的独立危险因素(HR=1.091;95%CI:1.015,1.173;p=0.019)。
- cT1c为复发的独立危险因素(HR=68.436;95%CI:2.797,1674.415;p=0.010)。
- cT1b患者以总肿瘤大小3.0 cm为界二分,总肿瘤大小>3.0 cm者预后显著更差(HR=3.796;95%CI:1.006,14.317;p=0.049)。
- cT1b且总肿瘤大小>3.0 cm与cT1c的复发概率无显著差异(p=0.915)。
临床应用与阅片要点
- 作者认为,cT1b且总肿瘤大小>3.0 cm的肿瘤升级分期可能更合适。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim was to investigate the effect of clinico-radiologic variables, including total tumor (Ttotal) size and clinical T category, on the prognosis of patients with stage IA (T1N0M0) lung adenocarcinomas appearing as part-solid nodules (PSNs).
METHODS: This institutional review board-approved retrospective study included 506 patients (male:female = 200:306; median age, 62 years) with PSNs of the adenocarcinoma spectrum in clinical stage IA who underwent standard lobectomy at a single tertiary medical center. Prognostic stratification of the patients in terms of disease-free survival was analyzed with variables including age, sex, Ttotal size, solid portion size, clinical T category, and tumor location using univariate and subsequent multivariate Cox regression analysis. Subgroup analysis was performed to reveal the effect of the Ttotal size at each clinical T category.
RESULTS: Multivariate Cox regression analysis demonstrated that Ttotal size*cT1b [interaction term; hazard ratio (HR) = 1.091; 95% confidence interval (CI): 1.015, 1.173; p = 0.019] and cT1c (HR = 68.436; 95% CI: 2.797, 1674.415; p = 0.010) were independent risk factors for the tumor recurrence. When patients with cT1b were dichotomized based on a Ttotal size cutoff of 3.0 cm, PSNs with Ttotal > 3.0 cm showed a significantly worse outcome (HR = 3.796; 95% CI: 1.006, 14.317; p = 0.049). No significant difference was observed in the probability of recurrence between cT1b with Ttotal > 3.0 cm and cT1c (p = 0.915).
CONCLUSIONS: Ttotal size is a significant prognostic factor in adenocarcinoma patients in cT1b without lymph node or distant metastasis. PSNs in cT1b with Ttotal > 3.0 cm have a comparable risk of lung cancer recurrence to those in cT1c.
KEY POINTS: • Current T descriptor was a powerful prognostic factor in stage IA adenocarcinomas appearing as part-solid nodules. • Total tumor size further stratified risk of recurrence of adenocarcinomas in cT1b. • Upstaging of tumors in cT1b with total tumor size > 3.0 cm may be more appropriate.
引用
- Kim H, Goo JM, Suh YJ, et al. Implication of total tumor size on the prognosis of patients with clinical stage IA lung adenocarcinomas appearing as part-solid nodules: Does only the solid portion size matter? Eur Radiol. 2018. PMID: 30132107. doi:10.1007/s00330-018-5685-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。